Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III
HEARTS Trial for Thoracic Cancers
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the…
- Conditions
- Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III
- Trial name
- NCT07132918
- Testing
- MRgART, LINAC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
This is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and…
- Conditions
- Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy, Neoadjuvant Chemoimmunotherapy, Surgery
- Trial name
- NCT07608159
- Testing
- Stereotactic body radiotherapy (SBRT), neoadjuvant immunotherapy, Neoadjuvant Chemotherapy
- Volunteers
- 201 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03191149
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test
- Where
- 347 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Non-small-cell Lung Cancer
Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
The phase II, randomised Study is to explore the efficacy and safety of nivolumab as consolidation therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following…
- Trial name
- NCT04085250
- Testing
- Neoadjuvant therapy, Chemotherapy concurrent with radiotherapy, Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer NSCLC
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Aim of this phase 2 study is to explore the safety and efficacy of thoracic re-irradiation +/- SBRT to oligometastases (<3) followed after an interval of 2 weeks by durvalumab and ceralasertib for patients with thoracic relapses…
- Trial name
- AUSTRAL (NCT06680050)
- Testing
- Durvalumab (MEDI4736), Ceralasertib, radiotherapy
- Where
- 9 sites in Italy, Switzerland
- Volunteers
- 21 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Non-Small Cell Lung Cancer
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
The rationale for this multicenter, phase II trial is to examine the impact of carboplatin/paclitaxel with bevacizumab in the preoperative treatment of patients with stage IB (> 4.0 cm), II, and select stage III NSCLC.
- Trial name
- NCT00960297
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- SCRI Development Innovations, LLC
Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
This is an open-label, phase II, exploratory and multi-centre clinical trial. 37 Limited stage SCLC patients not eligible for concurrent chemo-radiotherapy will be enroll.
- Conditions
- Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms
- Trial name
- MERLIN (NCT07242547)
- Testing
- Tarlatamab
- Where
- 20 sites in Spain
- Volunteers
- 37 people
- Sponsor
- Fundación GECP
Non Small Cell Lung Cancer (NSCLC)
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in…
- Trial name
- NCT07276789
- Testing
- LS301-IT 0.1 mg/kg
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Integro Theranostics
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery.
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT02194738
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 1,660 sites in United States, Guam and 1 more
- Volunteers
- 7,458 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00268255
- Testing
- gefitinib, adjuvant therapy, enzyme inhibitor therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase II trial to study the effectiveness of bortezomib in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00040768
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
Src expression has been identified in a majority of Non-Small Cell Lung Cancer (NSCLC) cell lines and there is preclinical evidence that Src family kinases may be important in hypoxic growth and angiogenesis in NSCLC.
- Trial name
- TOP0706 (NCT00564876)
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Duke University
Lung Cancer, Non Small Cell Lung Cancer
Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)
Experiments suggest that low molecular weight heparin (LMWH) inhibits tumor growth and metastasis. Studies in humans suggest that LMWH is associated with a higher survival in patients with cancer related thrombosis.
- Trial name
- TILT (NCT00475098)
- Testing
- Tinzaparin sodium 100 UI/Kg/OD for 12 weeks
- Where
- France
- Volunteers
- 553 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Phase II trial to study the effectiveness of combining suramin, paclitaxel, and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00006929
- Testing
- suramin, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Non Small Cell Lung Cancer
Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
In this trial, subjects with chemo-naive advanced non-small cell lung cancer (NSCLC) were assigned to chemotherapy using a genomic-based predictor for platinum sensitivity.
- Trial name
- TOP0602 (NCT00509366)
- Testing
- Cisplatin & Gemcitabine, Cisplatin & Pemetrexed, Docetaxel & Gemcitabine
- Where
- 8 sites in United States
- Volunteers
- 101 people
- Sponsor
- Duke University
Non Small Cell Lung Cancer
ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC
Assess the PFS/ORR/OS of ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in first Treatment of NSCLC
- Trial name
- NCT01810367
- Testing
- ABX Combined With Cisplatin, Gemcitabine Combined With Cisplatin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Fudan University
Lung Cancer
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00960999
- Testing
- Single-fraction stereotactic body radiation therapy (SBRT), Multiple-fraction stereotactic body radiation therapy (SBRT)
- Where
- 38 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00005630
- Testing
- ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC).
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04310007
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 611 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.